Marcelli M, Cunningham G R, Haidacher S J, Padayatty S J, Sturgis L, Kagan C, Denner L
Department of Medicine, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas 77030, USA.
Cancer Res. 1998 Jan 1;58(1):76-83.
The goals of this work were to establish a reproducible and effective model of apoptosis in a cell line derived from advanced prostate cancer and to study the role of the caspase family of proteases in mediating apoptosis in this system. The study involved the use of the prostate cancer cell line LNCaP. Apoptosis was induced using the hydroxymethyl glutaryl CoA reductase inhibitor, lovastatin, and was evaluated by agarose gel electrophoresis of genomic DNA, morphological criteria, and terminal deoxynucleotidyl transferase-mediated nick end labeling. Caspases were studied by catalytic activity, mRNA induction, and protein processing. Lovastatin (30 microM) was an effective inducer of apoptosis, causing changes that were evident after 48 h and essentially complete after 96-120 h of treatment. These effects were prevented by the simultaneous addition of mevalonate (300 microM) to the culture medium. Lovastatin induced a proteolytic activity that was able to cleave the enzyme poly(ADP-ribose) polymerase and the substrate Z-DEVD-AFC, which is modeled after the P1-P4 amino acids of the poly(ADP-ribose) polymerase cleavage site. Caspase-7, but not caspase-3, underwent proteolytic activation during lovastatin-induced apoptosis, an effect prevented by mevalonate. Caspase-7 was the only detected interleukin 1beta converting enzyme family protease with DEVD cleavage activity that exhibited lovastatin-induced mRNA up-regulation. Again, mevalonate blocked this effect. Lovastatin-induced apoptosis also was prevented when the caspase inhibitors Z-DEVD-CH2F or Z-VAD-CH2F (100 microM) where added to the medium. These studies have identified lovastatin as a powerful inducer of apoptosis in the cell line LNCaP. Caspase activation was a necessary event for LNCaP cells to undergo apoptosis during treatment with lovastatin. Of the caspases tested, only caspase-7 underwent proteolytic activation after stimulation with lovastatin. Identification of caspase-7 as a potential mediator of lovastatin-induced apoptosis broadens our knowledge of the molecular events associated with programmed cell death in a cell line derived from prostatic epithelium.
这项工作的目标是在源自晚期前列腺癌的细胞系中建立一种可重复且有效的细胞凋亡模型,并研究蛋白酶半胱天冬酶家族在介导该系统细胞凋亡中的作用。该研究使用了前列腺癌细胞系LNCaP。使用羟甲基戊二酰辅酶A还原酶抑制剂洛伐他汀诱导细胞凋亡,并通过基因组DNA的琼脂糖凝胶电泳、形态学标准以及末端脱氧核苷酸转移酶介导的缺口末端标记来评估。通过催化活性、mRNA诱导和蛋白质加工来研究半胱天冬酶。洛伐他汀(30微摩尔)是一种有效的细胞凋亡诱导剂,在处理48小时后引起明显变化,在96 - 120小时后基本完成。同时向培养基中添加甲羟戊酸(300微摩尔)可阻止这些效应。洛伐他汀诱导了一种蛋白水解活性,该活性能够切割聚(ADP - 核糖)聚合酶和底物Z - DEVD - AFC,后者是根据聚(ADP - 核糖)聚合酶切割位点的P1 - P4氨基酸构建的模型。在洛伐他汀诱导的细胞凋亡过程中,半胱天冬酶 - 7而非半胱天冬酶 - 3经历了蛋白水解激活,甲羟戊酸可阻止这种效应。半胱天冬酶 - 7是唯一检测到的具有DEVD切割活性且表现出洛伐他汀诱导的mRNA上调的白细胞介素1β转换酶家族蛋白酶。同样,甲羟戊酸阻断了这种效应。当向培养基中添加半胱天冬酶抑制剂Z - DEVD - CH2F或Z - VAD - CH2F(100微摩尔)时,洛伐他汀诱导的细胞凋亡也被阻止。这些研究已确定洛伐他汀是LNCaP细胞系中一种强大的细胞凋亡诱导剂。半胱天冬酶激活是LNCaP细胞在用洛伐他汀处理期间发生细胞凋亡的必要事件。在所测试的半胱天冬酶中,只有半胱天冬酶 - 7在受到洛伐他汀刺激后经历了蛋白水解激活。将半胱天冬酶 - 7鉴定为洛伐他汀诱导的细胞凋亡的潜在介导因子,拓宽了我们对源自前列腺上皮的细胞系中与程序性细胞死亡相关的分子事件的认识。